A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Launched by INTERMUNE · Oct 10, 2002
Trial Information
Current as of June 20, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Male or Female 20-79 years old
About Intermune
Intermune, a biopharmaceutical company, specializes in the development and commercialization of innovative therapies for rare and serious diseases, particularly in the fields of pulmonary and liver diseases. With a strong commitment to advancing patient care through cutting-edge research, Intermune leverages its expertise in drug development to bring forward novel treatment options that address unmet medical needs. The company emphasizes collaboration and innovation, working closely with healthcare professionals, researchers, and regulatory bodies to ensure the successful progression of its clinical trials and the delivery of effective therapies to patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Patients applied
Trial Officials
Williamson Bradford, MD
Study Director
InterMune
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials